Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Elisa Mancuso

Showing results (11-20 of 147) with videos related to

Pageof 15
Sort By:
Drug Design, Development and Therapy|April 15, 2014
Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophiliasMaria Elisa Mancuso, Pier Mannuccio Mannucci
Seminars in Thrombosis and Hemostasis|November 24, 2015
Thrombin Generation Assay as a Laboratory Monitoring Tool during Bypassing Therapy in Patients with Hemophilia and InhibitorsMaria Elisa Mancuso, Maria Rosaria Fasulo
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 6, 2022
Managing invasive procedures in haemophilia patients with limited resources, extended half-life concentrates or non-replacement therapies in 2022Maria Elisa Mancuso, Shashikant Apte, Cedric Hermans
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 16, 2025
The Mirage of Factor Equivalence: Examining the Complexities of Non-Factor Therapies in HaemophiliaYesim Dargaud, Arianna Colombo, Maria Elisa Mancuso
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 14, 2024
Benefits and risks of non-factor therapies: Redefining haemophilia treatment goals in the era of new technologiesMaria Elisa Mancuso, Stacy E Croteau, Robert Klamroth
Blood|March 14, 2012
How we choose factor VIII to treat hemophiliaPier Mannuccio Mannucci, Maria Elisa Mancuso, Elena Santagostino
Lancet (London, England)|January 18, 2021
The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editingMaria Elisa Mancuso, Johnny N Mahlangu, Steven W Pipe
Expert Review of Hematology|March 19, 2020
Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigmsDavid Lillicrap, Karin Fijnvandraat, Guy Young, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 6, 2022
Befovacimab, an anti-tissue factor pathway inhibitor antibody: Early termination of the multiple-dose, dose-escalating Phase 2 study due to thrombosisMaria Elisa Mancuso, Sheila J M Ingham, Marc Kunze
Haematologica|April 6, 2006
Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitorsAngiola Rocino, Elena Santagostino, Maria Elisa Mancuso, et al.
Pageof 15

Showing results (11-20 of 147) with videos related to

Sort By:
Pageof 15
Drug Design, Development and Therapy|April 15, 2014
Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophiliasMaria Elisa Mancuso, Pier Mannuccio Mannucci
Seminars in Thrombosis and Hemostasis|November 24, 2015
Thrombin Generation Assay as a Laboratory Monitoring Tool during Bypassing Therapy in Patients with Hemophilia and InhibitorsMaria Elisa Mancuso, Maria Rosaria Fasulo
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 6, 2022
Managing invasive procedures in haemophilia patients with limited resources, extended half-life concentrates or non-replacement therapies in 2022Maria Elisa Mancuso, Shashikant Apte, Cedric Hermans
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 16, 2025
The Mirage of Factor Equivalence: Examining the Complexities of Non-Factor Therapies in HaemophiliaYesim Dargaud, Arianna Colombo, Maria Elisa Mancuso
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 14, 2024
Benefits and risks of non-factor therapies: Redefining haemophilia treatment goals in the era of new technologiesMaria Elisa Mancuso, Stacy E Croteau, Robert Klamroth
Blood|March 14, 2012
How we choose factor VIII to treat hemophiliaPier Mannuccio Mannucci, Maria Elisa Mancuso, Elena Santagostino
Lancet (London, England)|January 18, 2021
The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editingMaria Elisa Mancuso, Johnny N Mahlangu, Steven W Pipe
Expert Review of Hematology|March 19, 2020
Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigmsDavid Lillicrap, Karin Fijnvandraat, Guy Young, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 6, 2022
Befovacimab, an anti-tissue factor pathway inhibitor antibody: Early termination of the multiple-dose, dose-escalating Phase 2 study due to thrombosisMaria Elisa Mancuso, Sheila J M Ingham, Marc Kunze
Haematologica|April 6, 2006
Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitorsAngiola Rocino, Elena Santagostino, Maria Elisa Mancuso, et al.
Pageof 15